HomeSGEN • BMV
Seagen Ord Shs
$0.00
Mar 27, 2:23:10 PM GMT-6 · MXN · BMV · Disclaimer
StockMX listed securityUS headquartered
Previous close
$3,711.48
Year range
$3,711.48 - $3,711.48
Market cap
43.15B USD
P/E ratio
-
Dividend yield
-
Financials
Income Statement
Revenue
Net income
(USD)Sep 2023Y/Y change
Revenue
648.65M27.11%
Operating expense
262.69M24.86%
Net income
-215.79M-13.09%
Net profit margin
-33.2711.02%
Earnings per share
-1.15-11.65%
EBITDA
-209.33M-19.47%
Effective tax rate
0.26%
Total assets
Total liabilities
(USD)Sep 2023Y/Y change
Cash and short-term investments
1.24B-29.86%
Total assets
3.63B0.42%
Total liabilities
1.08B35.94%
Total equity
2.55B
Shares outstanding
188.66M
Price to book
274.52
Return on assets
-16.01%
Return on capital
-21.12%
Net change in cash
(USD)Sep 2023Y/Y change
Net income
-215.79M-13.09%
Cash from operations
-35.82M58.21%
Cash from investing
142.49M119.31%
Cash from financing
15.52M-15.59%
Net change in cash
119.90M1,958.05%
Free cash flow
71.52M1,141.10%
About
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union. To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Founded
Jul 15, 1997
Website
Employees
3,256
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu